HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 29, 2016 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf, VP Scientific & Regulatory Affairs will be presenting at the ISRASTEM 2016 and the 6th Israel Stem Cell Society (ISCS) joint annual meeting on Tuesday April 5th 2016 at 11:30 am at the Intercontinental Conference Center in Tel Aviv, Israel.

Dr. Gothelf will present the combined results of the Phase 1/2 and Phase 2a clinical studies that investigated NurOwn® in ALS.

About ISRASTEM  2016 and the 6th International Israel Stem Cell Society joint annual meeting -

The ISRASTEM 2016 and 6th International Israel Stem Cell Society joint annual meeting will focus on novel developments in stem cells, cell therapy and regenerative medicine in both academia and industry. The conference and exhibition will take place April 5th-6th, 2016, at the Intercontinental Conference Center in Tel Aviv, Israel.

Leading researchers from academia, industry, and medical centers will present their recent and most exciting achievements. The program will include basic science and translational sessions in fields such as cardiovascular, cerebrospinal, diabetes, metabolic and hematological diseases, immunotherapy and reconstructive surgery along with sessions on regulatory and production challenges and commercialization. Basic stem cell science sessions will include the biology of pluripotency, hematopoiesis, stem cells in disease, epigenetics of stem cells, programming of adult tissues and stem cells in tissue engineering and regenerative medicine. For more information, refer to http://bioforumconf.com/israstem16

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been safely administered to over 60 patients with ALS in clinical trials conducted in Israel, as well as in its ongoing randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause Brainstorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with Brainstorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in Brainstorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on Brainstorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts

Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

Logo - http://photos.prnewswire.com/prnh/20141006/150511

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-the-israstem-2016-and-the-6th-international-israel-stem-cell-society-joint-annual-meeting-300241872.html

SOURCE Brainstorm Cell Therapeutics Inc.